HbA1c Variability and Cardiovascular Events

被引:2
作者
Mehring M. [1 ]
Donnachie E. [2 ]
Schneider A. [1 ]
机构
[1] Institute of General Practice, University Hospital Klinikum rechts der Isar, Technische Universität München, Munich
[2] Association of Statutory Health Insurance Physicians of Bavaria-Munich, Elsenheimerstraße 39, Munich
关键词
Cardiovascular events; HbA[!sub]1c[!/sub] variability; Health services research; Severe adverse events;
D O I
10.1007/s12170-016-0501-x
中图分类号
学科分类号
摘要
Due to its high and increasing prevalence, type 2 diabetes mellitus is becoming more and more of a global public health burden. Effective measures are required to prevent diabetes-related morbidity and the resulting premature death. The effect of long-term glycemic fluctuations in patients with diabetes mellitus, referred to as HbA1c variability, has been the subject of intensive discussion. Whereas the mean HbA1c value is already established as a risk factor for vascular complications, an accumulation of findings makes a compelling case that HbA1c variability adds further predictive value. Recent studies raise the possibility that a reduced HbA1c variability may inhibit hyperglycemia-related diseases without increasing the risk of hypoglycemia. Taken as a whole, the present evidence demonstrates a clear association between HbA1c variability and cardiovascular events in patients with type 1 and type 2 diabetes. Nevertheless, there exists to date no standardized definition or method of measuring HbA1c variability. To advance further research, it would be helpful to reach consensus on a precise definition of HbA1c variability. © 2016, Springer Science+Business Media New York.
引用
收藏
相关论文
共 33 条
  • [11] Hirakawa Y., Arima H., Zoungas S., Ninomiya T., Cooper M., Hamet P., Mancia G., Poulter N., Harrap S., Woodward M., Chalmers J., Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial, Diabetes Care, 37, pp. 2359-2365, (2014)
  • [12] Rodriguez-Segade S., Rodriguez J., Garcia Lopez J.M., Casanueva F.F., Camina F., Intrapersonal HbA(1c) variability and the risk of progression of nephropathy in patients with type 2 diabetes, Diabet Med, 29, pp. 1562-1566, (2012)
  • [13] Skriver M.V., Sandbaek A., Kristensen J.K., Stovring H., Relationship of HbA1c variability, absolute changes in HbA1c, and all-cause mortality in type 2 diabetes: a Danish population-based prospective observational study, BMJ Open Diabetes Res Care, 3, (2015)
  • [14] Frontoni S., Di Bartolo P., Avogaro A., Bosi E., Paolisso G., Ceriello A., Glucose variability: an emerging target for the treatment of diabetes mellitus, Diabetes Res Clin Pract, 102, pp. 86-95, (2013)
  • [15] Ceriello A., Postprandial hyperglycemia and diabetes complications: is it time to treat?, Diabetes, 54, pp. 1-7, (2005)
  • [16] Ceriello A., Ihnat M.A., ‘Glycaemic variability’: a new therapeutic challenge in diabetes and the critical care setting, Diabet Med, 27, pp. 862-867, (2010)
  • [17] Ihnat M.A., Thorpe J.E., Ceriello A., Hypothesis: the ‘metabolic memory’, the new challenge of diabetes, Diabet Med, 24, pp. 582-586, (2007)
  • [18] Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., Quagliaro L., Ceriello A., Giugliano D., Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress, Circulation, 106, pp. 2067-2072, (2002)
  • [19] Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J., Colette C., Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes, JAMA, 295, pp. 1681-1687, (2006)
  • [20] Ceriello A., Esposito K., Piconi L., Ihnat M.A., Thorpe J.E., Testa R., Boemi M., Giugliano D., Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients, Diabetes, 57, pp. 1349-1354, (2008)